ArticleOncotarget2017
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Matrix glycosaminoglycans and proteoglycans in human cornea organoids and similarities with fetal corneal stages.The ocular surface · 2025Article
- Trehalose extricates impaired mitochondrial and autophagy dysregulation in patient iPSC-derived macular corneal dystrophy disease model.Stem cell research & therapy · 2024Article
- Genetic implications of CHST6 gene mutations and their corneal microstructural changes in macular corneal dystrophy patients.Molecular vision · 2024Article
- Endoplasmic reticulum stress: molecular mechanism and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Novel compound heterozygous mutations in theAnnals of translational medicine · 2021Article
- Evaluation of the Genetic Variation Spectrum Related to Corneal Dystrophy in a Large Cohort.Frontiers in cell and developmental biology · 2021Article
- CHST6 mutations identified in Iranian MCD patients and CHST6 mutations reported worldwide identify targets for gene editing approaches including the CRISPR/Cas system.International ophthalmology · 2020Article
- Novel Mutations inFrontiers in cell and developmental biology · 2020Article
- Impairment of the autophagy-lysosomal pathway and activation of pyroptosis in macular corneal dystrophy.Cell death discovery · 2020Article
- A comprehensive evaluation of 181 reportedAging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macular corneal dystrophy (MCD) is an autosomal recessive disorder mainly caused by gene mutations of carbohydrate sulfotransferase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.